Climb Bio Earnings Estimates, EPS & Revenue | NASDAQ:CLYM

Comments

Climb Bio Inc Earnings Estimates

CLYMNASDAQ

Trade with Public

$8.85

0.222.55%

At close: Apr 13, 5:00 PM EST

$9.06

0.434.98%

Pre-Market: 6:41 AM EST

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Climb Bio Earnings Estimates, EPS & Revenue | NASDAQ:CLYM

Climb Bio (CLYM) is scheduled to report Q1 earnings on May 13, 2026. Analysts estimate EPS of $-0.29 and quarterly revenue of N/A.

In the most recent quarter (Q4), Climb Bio reported EPS of $-0.26, missing estimates of $-0.20 by 0.30%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Climb Bio has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Climb Bio has averaged an EPS surprise of 0.27% and a revenue surprise of 0.00%.

Earnings Date

May 13

EPS Estimate

$-0.290

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–

Climb Bio Earnings History

Analyze the earnings history of Climb Bio using advanced sorting and filters.

Loading calendar...

Climb Bio (CLYM) Earnings Per Share

The chart below shows Climb Bio's reported EPS compared to analyst estimates over recent quarters.

Climb Bio (CLYM) Revenue

The chart below shows Climb Bio's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Climb Bio (NASDAQ:CLYM) reporting earnings?

Climb Bio (CLYM) is scheduled to report earnings on May 13, 2026. The last reported earnings were for reported on March 5, 2026 for Q4.

What were the latest earnings per share (EPS) for Climb Bio (NASDAQ:CLYM)?

The Actual EPS was $-0.26, which missed the estimate of $-0.20.

What were Climb Bio’s (NASDAQ:CLYM) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL

$5.17

-0.58%

Monopar Therapeutics Inc

Eupraxia Pharmaceuticals Inc

Century Therapeutics Inc

NASDAQ:IPSC

$2.36

-0.42%

Emergent BioSolutions Inc

NYSE:EBS

$8.66

Climb Bio Earnings Estimates, EPS & Revenue | NASDAQ:CLYM

Climb Bio (CLYM) is scheduled to report Q1 earnings on May 13, 2026. Analysts estimate EPS of $-0.29 and quarterly revenue of N/A.

In the most recent quarter (Q4), Climb Bio reported EPS of $-0.26, missing estimates of $-0.20 by 0.30%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Climb Bio has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Climb Bio has averaged an EPS surprise of 0.27% and a revenue surprise of 0.00%.

Earnings Date

May 13

EPS Estimate

$-0.290

Quarterly Revenue Estimate

–

Annual Revenue
(as of Dec 31)

–